Rafferty Asset Management’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Rafferty Asset Management’s Portfolio PNT Stock Details PNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-223,080	Closed	-$1.49M	–	1104
2023 Q3	$1.49M	Buy	223,080 +27,436	+14%	+$228K	0.01%	699
2023 Q2	$1.77M	Buy	195,644 +24,909	+15%	+$220K	0.01%	682
2023 Q1	$1.24M	Sell	170,735 -126,643	-43%	-$939K	0.01%	745
2022 Q4	$2.17M	Buy	297,378 +148,802	+100%	+$1.1M	0.02%	548
2022 Q3	$1.15M	Buy	148,576 +90,366	+155%	+$767K	0.01%	633
2022 Q2	$396K	Buy	+58,210	New	+$445K	﹤0.01%	839

Other funds holding PNT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Rafferty Asset Management's PNT Position: Q4 2023 in Review

Rafferty Asset Management sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q4 2023, closing a stake of 223,080 shares — an estimated $1.49M sold.

Rafferty Asset Management first reported a position in PNT in Q2 2022 and held it in 6 quarters. The position peaked at $2.17M in Q4 2022. 1 fund tracked by Wall St. Rank holds PNT as of Q4 2023.

Rafferty Asset Management reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Rafferty Asset Management sold 223,080 POINT Biopharma Global Inc. Common Stock shares in Q4 2023, an estimated $1.49M.
Rafferty Asset Management first reported a position in POINT Biopharma Global Inc. Common Stock in Q2 2022 and held it in 6 quarters.
Rafferty Asset Management's POINT Biopharma Global Inc. Common Stock position peaked at $2.17M in Q4 2022.
1 fund tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q4 2023.

Based on Rafferty Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.